Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases

Table 3

Enthalpy of fusion (J·mg⁻¹) and crystallinity index for determining the solubility of buparvaquone in solids lipids by differential scanning calorimetry.

Lipid				CI (%)	CI (%)
	(J·mg^−1)	(J·mg^−1) 1st	(J·mg^−1) 2nd	1st	2nd
Witepsol E85	136.0	33.2	33.3	48.8	49.0
Softisan 154	136.0	42.2	33.4	62.1	49.1
Gelucire 50/13	136.0	59.4	34.4	40.6	50.6
Gelucire 44/14	136.0	47.6	35.5	70.0	52.2
Precirol ATO 5	136.0	54.9	37.7	80.7	55.4
Sterotex HM	136.0	51.5	44.0	75.7	64.7
Dynsan P60	136.0	59.4	57.9	87.4	85.1
Compritol 888	136.0	66.5	67.3	97.8	99.0

BPQ: buparvaquone; BPQ-PM: BPQ and lipid physical mixture; CI: crystallinity index = (BPQ enthalpy in lipid mixture (J·mg⁻¹ (proportion of BPQ and lipid)/BPQ enthalpy of fusion (J·mg⁻¹)) × 100; 1st and 2nd heating cycles.